Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer (Q36363701)

13 August 2017

Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer (English)

1 reference

13 August 2017

phase II clinical trial

0 references

4

Tanios Bekaii-Saab

1 reference

13 August 2017

Bhuvaneswari Ramaswamy

1

1 reference

13 August 2017

Ewa Mrozek

2

1 reference

13 August 2017

John Philip Kuebler

3

1 reference

13 August 2017

Eric H Kraut

5

1 reference

13 August 2017

21 October 2009

1 reference

Investigational New Drugs

13 August 2017

1 reference

13 August 2017

29

1 reference

13 August 2017

2

1 reference

13 August 2017

347-351

1 reference

Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3486428

Phase II study of pyrazoloacridine in metastatic renal cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3486428

Phase II trial of pyrazoloacridine in children with solid tumors: a Pediatric Oncology Group phase II study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3486428

Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3486428

Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3486428

The pyrazoloacridines: approaches to the development of a carcinoma-selective cytotoxic agent

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3486428

Phase II trial of pyrazoloacridine in advanced non-small cell carcinoma of the lung--a Kansas Cancer Institute and Thompson Cancer Survival Center Study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3486428

Activity of the pyrazoloacridines against multidrug-resistant tumor cells.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3486428

A phase II trial of pyrazoloacridine (PZA) in squamous carcinoma of the cervix--a Gynecologic Oncology Group Study

28 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-009-9338-1

Pyrazoloacridine for the treatment of hormone-refractory prostate cancer

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-009-9338-1

Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-009-9338-1

Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3486428

Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3486428

Cytotoxicity and DNA damage associated with pyrazoloacridine in MCF-7 breast cancer cells

5 December 2018

1 reference

12 December 2020

Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma

1 reference

12 December 2020

Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934)

1 reference

12 December 2020

Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors

1 reference

12 December 2020

A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer

1 reference

12 December 2020

Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro

1 reference

12 December 2020

10.1007/S10637-009-9338-1

Identifiers

DOI

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

19844661

1 reference